Resolution of the Working Meeting of Experts in “Dermatology”: Possibilities of systemic therapy of atopic dermatitis with selective immunosuppressants
- Authors: Bakulev A.L.1, Vishneva E.A.2,3, Elisyutina O.G.4, Ilyina N.I.4, Karamova A.E.5, Kokhan M.M.6, Kubanov A.A.5, Monakhov K.N.7, Namazova-Baranova L.S.2,3, Novik G.A.8, Olisova O.Y.9, Revyakina V.A.10, Sokolovskiy E.V.7, Fedenko E.S.4, Khobeysh M.M.7
-
Affiliations:
- Central State Medical Academy of Department of Presidential Affairs
- The Russian National Research Medical University named after N.I. Pirogov
- Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences
- National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia
- State Scientific Center for Dermatovenereology and Cosmetology
- Ural Research Institute for Dermatovenerology and Immunopatology
- Academician I.P. Pavlov First St. Petersburg State Medical University
- Saint-Petersburg State Pediatric Medical University
- First Sechenov Moscow State Medical University (Sechenov University)
- Federal Research Center of Nutrition, Biotechnology and Food Safety
- Issue: Vol 19, No 2 (2022)
- Pages: 259-269
- Section: Clinical practice guidelines
- URL: https://journals.rcsi.science/raj/article/view/121768
- DOI: https://doi.org/10.36691/RJA1546
- ID: 121768
Cite item
Full Text
Abstract
On February 19, 2022, a working meeting of experts on the problem of atopic dermatitis was held in Moscow under the chairmanship of the Director of the State Scientific Center for Dermatovenereology and Cosmetology of the Ministry of Health of Russia, Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences A.A. Kubanov. Also in attendance was the Academician of the Russian Academy of Sciences, Chief Freelance Children’s Specialist in Preventive Medicine, Head of the Research Institute of Pediatrics and Children’s Health of the Central Clinical Hospital of the Russian Academy of Sciences of the Ministry of Science, and Higher Education of the Russian Federation, Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences, L.S. Namazova-Baranova, and also the Deputy Director for Clinical Work ― Chief Physician of the Federal State Budgetary Institution “SSC” Institute of Immunology “FMBA of Russia” Doctor of Medical Sciences, Professor N.I. Ilyina.
The meeting raised germane issues of providing medical care, reducing the burden of the disease, and improving the quality of life of patients with atopic dermatitis. New possibilities and principles of systemic therapy in patients with moderate and severe atopic dermatitis were discussed. We analyzed data on a new representative of the small molecule class — the selective Janus kinase 1 inhibitor, upadacitinib, which was registered in the Russian Federation in June 2021. This analysis aimed to determine its place in atopic dermatitis therapy algorithms and the possibility of the impact of its use as a therapy on the quality of life of patients in relation to the burden of diseases.
The article has been published in several journals simultaneously with permission from authors and publishers. The parallel publication is available here: Capabilities of atopic dermatitis systemic therapy with selective immunosuppressors: resolution of the experts workshop of dermatology profile. Pediatric pharmacology. 2022;19(2):209–211. DOI: https://doi.org/10.15690/pf.v19i2.2424
Full Text
##article.viewOnOriginalSite##About the authors
Andrey L. Bakulev
Central State Medical Academy of Department of Presidential Affairs
Email: al_ba05@mail.ru
ORCID iD: 0000-0002-1450-4942
SPIN-code: 6708-7386
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowElena A. Vishneva
The Russian National Research Medical University named after N.I. Pirogov; Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences
Email: vishneva.e@yandex.ru
ORCID iD: 0000-0001-7398-0562
SPIN-code: 1109-2810
MD, Dr. Sci. (Med)
Russian Federation, Moscow; MoscowOlga G. Elisyutina
National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia
Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-code: 9567-1894
MD, Dr. Sci. (Med.)
Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522Natalya I. Ilyina
National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia
Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650
MD, Dr. Sci. (Med.), Professor
Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522Arfenya E. Karamova
State Scientific Center for Dermatovenereology and Cosmetology
Email: karamova@cnikvi.ru
ORCID iD: 0000-0003-3805-8489
SPIN-code: 3604-6491
MD, Cand. Sci. (Med.)
Russian Federation, MoscowMuza M. Kokhan
Ural Research Institute for Dermatovenerology and Immunopatology
Email: mkokhan@yandex.ru
ORCID iD: 0000-0001-6353-6644
SPIN-code: 3470-9306
MD, Dr. Sci (Med.), Professor
Russian Federation, YekaterinburgAlexey A. Kubanov
State Scientific Center for Dermatovenereology and Cosmetology
Email: alex@cnikvi.ru
ORCID iD: 0000-0002-7625-0503
SPIN-code: 8771-4990
MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences
Russian Federation, MoscowKonstantin N. Monakhov
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: knmonakhov@gmail.com
ORCID iD: 0000-0002-8211-1665
SPIN-code: 1837-2098
MD, Dr. Sci. (Med.), Professor
Russian Federation, Saint PetersburgLeyla S. Namazova-Baranova
The Russian National Research Medical University named after N.I. Pirogov; Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences
Email: leyla.s.namazova@gmail.com
ORCID iD: 0000-0002-2209-7531
SPIN-code: 1312-2147
MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences
Russian Federation, Moscow; MoscowGennadiy A. Novik
Saint-Petersburg State Pediatric Medical University
Email: ga_novik@mail.ru
ORCID iD: 0000-0002-7571-5460
SPIN-code: 6289-0209
MD, Dr. Sci. (Med.), Professor
Russian Federation, Saint PetersburgOlga Yu. Olisova
First Sechenov Moscow State Medical University (Sechenov University)
Email: olisovaolga@mail.ru
ORCID iD: 0000-0003-2482-1754
SPIN-code: 2500-7989
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowVera A. Revyakina
Federal Research Center of Nutrition, Biotechnology and Food Safety
Author for correspondence.
Email: 5356797@mail.ru
ORCID iD: 0000-0002-1149-7927
SPIN-code: 4607-0540
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowEvgeny V. Sokolovskiy
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: s40@mail.ru
ORCID iD: 0000-0001-7610-6061
SPIN-code: 6807-7137
MD, Dr. Sci. (Med.), Professor
Russian Federation, Saint PetersburgElena S. Fedenko
National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia
Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242
MD, Dr. Sci. (Med.), Professor
Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522Marianna M. Khobeysh
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: mkhobeysh@yandex.ru
ORCID iD: 0000-0001-8670-7223
SPIN-code: 4377-8101
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, Saint PetersburgReferences
- Clinical recommendations. Atopic dermatitis. 2021. (In Russ). Available from: https://cr.minzdrav.gov.ru. Accessed: 15.04.2022.
- Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: 10.1016/j.jaci.2017.04.004
- Krysanov IS, Krysanova VS, Karpov OI, Ermakova VY. The economic burden of severe atopic dermatitis in the Russian Federation. Qualitative Clin Pract. 2019;(4):4–14. (In Russ). doi: 10.1016/2588-0519-2019-4-4-14
- Faraz A, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020;100(12):adv00161. doi: 10.2340/00015555-3511
- Wohl Y, Wainstein J, Bar-Dayan Y. Atopic dermatitis in Israeli adolescents ― a large retrospective cohort study. Acta Derm Venereol. 2014;94(6):695–698. doi: 10.2340/00015555-1819
- Langenbruch A, Radtke M, Franzke N, et al. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J Eur Acad Dermatol Venereol. 2014;28(6): 719–726. doi: 10.1111/jdv.12154
- Kurbanov AA, Bogdanova EV. Organization and results of medical care in the profile of dermatovenerology in the Russian Federation. Results of 2018. Bulletin Dermatology Venereology. 2019;95(4):8–23. (In Russ). doi: 10.25208/0042-4609-2019-95-4-8-23
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. JEADV. 2018;32(5):657–682. doi: 10.1111/jdv.14891
- Shrestha S, Miao R, Wang L, et al. Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, medicare, and medical databases. Adv Ther. 2017; 34(8):1989–2006. doi: 10.1007/s12325-017-0582-z
- Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol. 2018;121(5):604–612.e3. doi: 10.1016/j.anai.2018.07.042
- Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. Allergy. 2015;70(10):1300–1308. doi: 10.1111/all.12685
- Schmitt J, Schwarz K, Baurecht H, et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol. 2016;137(1):130–136. doi: 10.1016/j.jaci.2015.06.029
- Sánchez-Pérez J, Daudén-Tello E, Mora AM, Lara Surinyac N. Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study. Actas Dermosifiliogr. 2013;104(1):44–52. doi: 10.1016/j.ad.2012.03.008
- Narala S, Hata TR. Adult atopic dermatitis with comorbid atopic disease is associated with increased risk of infections: a population-based cross-sectional study. Dermatol Ther (Heidelb). 2017;7(1): 111–121. doi: 10.1007/s13555-017-0172-7
- Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19(6):821–838. doi: 10.1007/s40257-018-0383-4
- Acharya P, Mathur M. Association of atopic dermatitis with vitiligo: a systematic review and meta-analysis. J Cosmet Dermatol. 2020;19(8):2016–2020. doi: 10.1111/jocd.13263
- Mocanu M, Vâta D, Alexa AI, et al. Atopic dermatitis ― beyond the skin. Diagnostics. 2021;11(9):1553. doi: 10.3390/diagnostics11091553
- Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1645–1651. doi: 10.1080/03007995.2016.1195733
- Augustin M, Radtke MA, Glaeske G, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015;231(1):35–40. doi: 10.1159/000381913
- Silverberg NB. A practical overview of pediatric atopic dermatitis, part 3: comorbidities, and measurement of disease burden. Cutis. 2016;97(6):408–412.
- Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. Exp Dermatol. 2018;27(4):409–417. doi: 10.1111/exd.13336
- Darlenski R, Kazandjieva J, Hristakieva E, et al. Atopic dermatitis as a systemic disease. Clin Dermatol. 2014;32(3):409–413. doi: 10.1016/j.clindermatol.2013.11.007
- Oliveira C, Torres T. More than skin deep: the systemic nature of atopic dermatitis. Eur J Dermatol. 2019;29(3):250–258. doi: 10.1684/ejd.2019.3557
- Brunner P, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18–25. doi: 10.1016/j.jid.2016.08.022
- Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi: 10.1111/jdv.16892
- Smolkin YS, Masalsky SS, Smolkina OY. Questions of the use of biological therapy in atopic dermatitis: emphasis on dupilumab. Allergology Immunology Pediatrics. 2020;61(2):27–40. (In Russ). doi: 10.24411/2500-1175-2020-10005
- Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1–23. doi: 10.1007/s13555-016-0170-1
- Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi: 10.1056/NEJMoa1314768
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891
- Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768–775. doi: 10.1111/bjd.15928
- Instructions for the medical use of the drug Mycophenolate mofetil. (In Russ). Available from: https://grls.rosminzdrav.ru/grls.aspx?s=Мофетил&m=mnn. Accessed: 15.04.2022.
- Instructions for the medical use of the drug Azathioprine. (In Russ). Available from: https://grls.rosminzdrav.ru/grls.aspx?s=Азатиоприн&m=mnn. Accessed: 15.04.2022.
- Instructions for the medical use of the drug Methotrexate. (In Russ). Available from: https://grls.rosminzdrav.ru/grls.aspx?s=Метотрексат&m=mnn. Accessed: 15.04.2022.
- Werfel T, Heratizadeh A, Aberer W, et al. Update “Systemic treatment of atopic dermatitis” of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges. 2021;19(1):151–168. doi: 10.1111/ddg.14371
- Instructions for medical use of the drug Dupixentt®. (In Russ). Available from: http://grls.rosminzdrav.ru/Default.aspx. Accessed: 15.04.2022.
- Instructions for the medical use of the drug Olumiant®. (In Russ). Available from: http://grls.rosminzdrav.ru/Default.aspx. Accessed: 15.04.2022.
- Instructions for the medical use of the drug SHANVAK 15 mg. (In Russ). Available from: http://grls.rosminzdrav.ru/Default.aspx. Accessed: 15.04.2022.
- Identification of candidates for systemic therapy in clinical trials of advanced systemic methods of treatment of atopic dermatitis phase 3. (In Russ). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02277743; https://www.clinicaltrials.gov/ct2/show/NCT03349060; https://www.clinicaltrials.gov/ct2/show/NCT03435081. Accessed: 15.04.2022.
- Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi: 10.1016/j.jaad.2014.03.030
- Kok WL, Yew YW, Thng TG. Comorbidities associated with severity of atopic dermatitis in young adult males: a national cohort study. Acta Derm Venereol. 2019;99(7):652–656. doi: 10.2340/00015555-3175
- Katayama I, Kohno Y, Akiyama K, et al. Japanese guideline for atopic dermatitis 2014. Allergol Int. 2014;63(3):377–398. doi: 10.2332/allergolint.14-RAI-0769
- Saeki H, Nakahara T, Tanaka A, et al. Clinical practice guidelines for the management of atopic dermatitis 2016. J Dermatol. 2016; 43(10):1117–1145. doi: 10.1111/1346-8138.13392
- The AAAAI offers information on Eczema (Atopic Dermatitis) symptoms, diagnosis, treatment and management. Available from: https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/eczema-(atopic-dermatitis)-overview. Accessed: 15.04.2022.
- Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46(12):1053–1101. doi: 10.1111/1346-8138.15090
- Krader C, Pharm BS. Systemic Treatment for Pediatric AD. Dermatology Times. 2021;42(7).
- Nygaard U, Vestergaard C, Deleuran M. Systemic treatment of severe atopic dermatitis in children and adults. Current Treatment Options Allergy. 2014;1(4):1–13. doi: 10.1007/s40521-014-0032-y
- Instructions for the medical use of the drug Cyclosporine. (In Russ). Available from: http://grls.rosminzdrav.ru/Default.aspx. Accessed: 15.04.2022.
- Simpson EL, Bieber T, Guttman-Yassky E, et al.; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10. 1056/NEJMoa1610020
- De Wijs LE, Bosma AL, Erler NS, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2020;182(2):418–426. doi: 10.1111/bjd.18179
- Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143–151. doi: 10.1016/j.jaad.2019.02.053
- McKenzie PL, Rangu S, Treat JR, Castelo-Soccio L. Experience using dupilumab for pediatric atopic dermatitis at a tertiary care center: Inadequate response and adverse events. Pediatr Dermatol. 2021;38(5):1178–1184. doi: 10.1111/pde.14799
- Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am acad Dermatol. 2022;86(3):628–636. doi: 10.1016/j.jaad.2021.06.017
- Howe W. Treatment of atopic dermatitis (eczema) ― UpToDate. Last updated: Mar 11, 2022. Available from: https://www.uptodate.com/contents/treatment-of-atopic-dermatitis-eczema/print?sectionName=Frequency%20of%20bathing&search=ambulatory-&topicRef=8349&anchor=H3882190426&source=see_link. Accessed: 15.04.2022.
- Cartron AM, Nguyen TH, Roh YS, et al. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. Clin Exp Dermatol. 2021;46(5):820–824. doi: 10.1111/ced.14567
- Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergologie Select. 2021;5:293–304. doi: 10.5414/ALX02272E
- Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797–1810. doi: 10.1111/jdv.17351
- Pereyra-Rodriguez JJ, Alcantara-Luna S, Domínguez-Cruz J, et al. Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis. Life (Basel). 2021;11(9):927. doi: 10.3390/life11090927
- Silverberg JI, Hong HC, Thyssen JP, et al. Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2022;12(5):1181–1196. doi: 10.1007/s13555-022-00721-1
- Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;(2):23. doi: 10.1186/s41927-018-0031-x
- Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865–875. doi: 10.1136/annrheumdis-2020-219012
- McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. doi: 10.1186/s13075-019-1964-1
- Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/S0140-6736(21)00588-2
- Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi: 10.1016/S0140-6736(21)00589-4
- Paller AS, Mendes-Bastos P, Eichenfield LF, et al. Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: A subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase III clinical trials. Br J Dermatol. 2021;185(3):e128–e129.
- Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from 2 pivotal, phase 3, randomized, double-blinded, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2). European Academy Dermatology Venerology Congress; 2020. D3T03.4B.
- Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/S0140-6736(21)00588-2
- Ardern-Jones MR, Beck L, Calimlim B, et al. Rapid symptom and sleep improvement with upadacitinib with or without topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis: results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up) ISAD 2021 (PE-21), Abstract from 11th George Rajka International Symposium on Atopic Dermatitis April 19–20, Korea. Seoul; 2021. P. 34.
- Eyerich K, Lynde CW, Calimlim B, et al. Rapid quality-of-life improvement with upadacitinib with or without topical corticosteroids (TCS) in moderate-tosevere atopic dermatitis: results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up) ISAD 2021 (PE-20), Abstract from 11th George Rajka International Symposium on Atopic Dermatitis April 19–20, Korea. Seoul; 2021. P. 34–35.
- Reich K, de Bruin-Weller MS, Deleuran M, et al. Eczema activity and severity index (EASI) and validated investigator global assessment of atopic dermatitis (VIGA-AD) response are associated with improvements in other outcome measures: an analysis of 3 phase 3 trials of upadacitinib in patients with moderate-to-severe atopic dermatitis, ISAD 2021 (PE-19) Abstract from 11th George Rajka International Symposium on Atopic Dermatitis April 19–20, Korea. Seoul; 2021. P. 34.
- Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021; 157(9):1047–1055. doi: 10.1001/jamadermatol.2021.3023
- Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404–413. doi: 10.1001/jamadermatol.2022.0029
- Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results. J Allergy Clin Immunol. 2022;149(3):977–987.e14. doi: 10.1016/j.jaci.2021.07.036